|
Use of the Mo.Ma proximal cerebral protection device (Invatec) with FDA-approved carotid stents in high-risk patients are 98 percent effective and proved to decrease the risk of stroke, according to results of the ARMOUR trial presented by Barry T. Katzen, MD, at the 35th annual Society of Interventional Radiology Scientific Meeting March 15.
Written by C.P. Kaiser
You can hardly blink today without hearing the words “conflict of interest.” And with good reason: to preserve the integrity of science despite the source of research funding.
|
C. R. Bard has received pre-market approval from the FDA to market its LifeStent FlexStar and FlexStar XL vascular stent systems for the treatment of occlusive disease in native superficial femoral arteries and proximal popliteal arteries.
Written by Barry T. Katzen, MD
A variety of ills would ensue if industry support for meetings dried up.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).